Joana brings more than 8 years of academic research and experience as well as Scientific writing and editing to her role as a Science and Research writer. She also served as a Postdoctoral Researcher at the Center for Neuroscience and Cell Biology in Coimbra, Portugal, where she also received her PhD in Health Science and Technologies, with a specialty in Molecular and Cellular Biology.
Patients being treated with a combination 5-alpha reductase inhibitor (5ARIs) and an alpha blocker may switch to 5ARIs alone with no worsening of lower urinary tract symptoms (LUTS), a new study ... Read more
A minimally invasive laser procedure known as HoLEP is becoming a popular alternative to the more established TURP in treating benign prostatic hyperplasia (BPH). According to a new Indian study, HoLEP’s advantages include ... Read more
Many patients with bothersome urinary symptoms of benign prostatic hyperplasia (BPH) consult a doctor about their condition, a new study says. In terms of treatment, these patients prefer those that ... Read more
A jasmine-derived organic compound called methyl jasmonate (MeJA) could be used in conjunction with standard therapies to treat men with enlarged prostates, according to a study with rates. The combination could ... Read more
Treating benign prostatic hyperplasia (BPH) with 5-alpha reductase inhibitors can increase breast size in men, a condition called gynecomastia, but they don’t raise a person’s risk of breast cancer, according to a ... Read more
Chronic prostate inflammation may trigger the development of benign prostatic hyperplasia (BPH) and urinary complications, according to a new study in which the researchers contend the prevalence of a certain ... Read more
Patients with benign prostatic hyperplasia (BPH) who are treated with enzyme 5-alpha reductase inhibitors (5-ARIs) are not at a higher risk of dying of prostate cancer than those using α-blockers, a new study reports. ... Read more